Safety, tolerability, pharmacokinetics, and pharmacodynamics of bi 685509, a soluble guanylyl cyclase activator, in healthy volunteers: results from two randomized controlled trials

HIGHLIGHTS

• What: This study evaluated the safety tolerability pharmacokinetics and pharmacodynamics of BI 685509 after oral single rising within each of the three dose groups (DGs) six subjects received BI 685509 (1.0 2.5 or 5.0 mg) and two received placebo (N = 24).
• Who: Diane Wong from the (UNIVERSITY) have published the article: Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials, in the Journal: (JOURNAL) of February/29,/2016
• How: Both studies were conducted in accordance with the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.